> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Requests EUA Revocation for Covid Combo
- URL: https://www.fdaweb.com/lilly-requests-eua-revocation-for-covid-combo/
- Published: 2024-03-08T12:00:00.000Z
- Updated: 2026-09-14T14:24:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156516

*Federal Register* notice: FDA is announcing the revocation of an Eli Lilly emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for treating Covid-19\. Lilly requested the revocation after telling FDA that all lots of bamlanivimab and etesevimab manufactured and labeled for use under the EUA have expired, and that it does not intend to offer this product in the U.S. going forward. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-05085.pdf?ref=fdaweb.com).